NO2015013I1 - Cabazitaxel acetonat, også betegnet acetonsolvat av cabazitaxel eller acetonsolvat av imetoksydocetaxel, eller acetonsolvat av 4-acetoksy-2¿-benzoyloksy-5ß,20-epoksy-1-hydroksy-ß,10ßdimetoksy-9-oksotaks-11-en-13¿-yl (2R,3S)-3-tertbutoksykarbonylamino-2-hydroksy-3-fenylpropionat - Google Patents

Cabazitaxel acetonat, også betegnet acetonsolvat av cabazitaxel eller acetonsolvat av imetoksydocetaxel, eller acetonsolvat av 4-acetoksy-2¿-benzoyloksy-5ß,20-epoksy-1-hydroksy-ß,10ßdimetoksy-9-oksotaks-11-en-13¿-yl (2R,3S)-3-tertbutoksykarbonylamino-2-hydroksy-3-fenylpropionat

Info

Publication number
NO2015013I1
NO2015013I1 NO2015013C NO2015013C NO2015013I1 NO 2015013 I1 NO2015013 I1 NO 2015013I1 NO 2015013 C NO2015013 C NO 2015013C NO 2015013 C NO2015013 C NO 2015013C NO 2015013 I1 NO2015013 I1 NO 2015013I1
Authority
NO
Norway
Prior art keywords
acetone solvate
cabazitaxel
hydroxy
methoxydocetaxel
oxotax
Prior art date
Application number
NO2015013C
Other languages
English (en)
Other versions
NO2015013I2 (no
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34224354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2015013(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO2015013I2 publication Critical patent/NO2015013I2/no
Publication of NO2015013I1 publication Critical patent/NO2015013I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO2015013C 2003-09-19 2015-04-22 Cabazitaxel acetonat, også betegnet acetonsolvat av cabazitaxel eller acetonsolvat av imetoksydocetaxel, eller acetonsolvat av 4-acetoksy-2¿-benzoyloksy-5ß,20-epoksy-1-hydroksy-ß,10ßdimetoksy-9-oksotaks-11-en-13¿-yl (2R,3S)-3-tertbutoksykarbonylamino-2-hydroksy-3-fenylpropionat NO2015013I1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0311016A FR2859996B1 (fr) 2003-09-19 2003-09-19 Solvat acetonique du dimethoxy docetaxel et son procede de preparation
PCT/FR2004/002344 WO2005028462A1 (fr) 2003-09-19 2004-09-16 Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Publications (2)

Publication Number Publication Date
NO2015013I2 NO2015013I2 (no) 2015-04-22
NO2015013I1 true NO2015013I1 (no) 2015-05-04

Family

ID=34224354

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20061714A NO335997B1 (no) 2003-09-19 2006-04-19 Dimetoksydocetaksel-acetonsolvat og fremgangsmåte for fremstilling derav
NO2015013C NO2015013I1 (no) 2003-09-19 2015-04-22 Cabazitaxel acetonat, også betegnet acetonsolvat av cabazitaxel eller acetonsolvat av imetoksydocetaxel, eller acetonsolvat av 4-acetoksy-2¿-benzoyloksy-5ß,20-epoksy-1-hydroksy-ß,10ßdimetoksy-9-oksotaks-11-en-13¿-yl (2R,3S)-3-tertbutoksykarbonylamino-2-hydroksy-3-fenylpropionat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20061714A NO335997B1 (no) 2003-09-19 2006-04-19 Dimetoksydocetaksel-acetonsolvat og fremgangsmåte for fremstilling derav

Country Status (38)

Country Link
US (1) US7241907B2 (no)
EP (1) EP1667986B1 (no)
JP (1) JP5010279B2 (no)
KR (1) KR101123588B1 (no)
CN (1) CN100429207C (no)
AR (1) AR045667A1 (no)
AU (1) AU2004274212B2 (no)
BE (1) BE2013C036I2 (no)
BR (1) BRPI0414492A8 (no)
CA (1) CA2539309A1 (no)
CR (1) CR8292A (no)
CY (2) CY1114575T1 (no)
DK (1) DK1667986T3 (no)
ES (1) ES2403149T4 (no)
FR (2) FR2859996B1 (no)
HK (1) HK1093340A1 (no)
HR (1) HRP20130322T1 (no)
HU (1) HUS1300025I1 (no)
IL (1) IL174240A (no)
LU (1) LU92172I2 (no)
MA (1) MA28045A1 (no)
ME (2) MEP11708A (no)
MX (1) MXPA06002639A (no)
MY (1) MY136668A (no)
NO (2) NO335997B1 (no)
NZ (1) NZ545835A (no)
PA (1) PA8612401A1 (no)
PE (1) PE20050870A1 (no)
PL (1) PL1667986T3 (no)
PT (1) PT1667986E (no)
RS (2) RS54614B1 (no)
RU (1) RU2342373C2 (no)
SI (1) SI1667986T1 (no)
TN (1) TNSN06086A1 (no)
TW (1) TWI382022B (no)
UA (1) UA87115C2 (no)
WO (1) WO2005028462A1 (no)
ZA (1) ZA200602255B (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007226937A1 (en) * 2006-03-21 2007-09-27 Dr. Reddy's Laboratories Ltd. Docetaxel polymorphs and processes
US7855591B2 (en) * 2006-06-07 2010-12-21 Atmel Corporation Method and system for providing a charge pump very low voltage applications
US7652522B2 (en) * 2006-09-05 2010-01-26 Atmel Corporation High efficiency low cost bi-directional charge pump circuit for very low voltage applications
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
AU2013205442B2 (en) * 2008-01-17 2016-05-12 Aventis Pharma S.A. Crystalline forms of dimethoxy docetaxel and methods for preparing same
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
MX2011001583A (es) 2008-08-11 2011-04-04 Nektar Therapeutics Conjugados de alcanoato polimericos de multiples brazos.
FR2945211A1 (fr) * 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
AU2015200149B2 (en) * 2009-10-29 2016-12-01 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
KR101712231B1 (ko) * 2009-10-29 2017-03-03 아벤티스 파마 소시에떼아노님 카바지탁셀의 신규한 항종양 용도
CA2708489A1 (en) * 2009-10-29 2011-04-29 Aventis Pharma S.A. Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
EA023950B1 (ru) * 2011-04-12 2016-07-29 Тева Фармасьютикалз Интернэшнл Гмбх Твердофазные формы кабазитаксела и способы их получения
WO2013024495A1 (en) * 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel
TWI526437B (zh) * 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
US8722900B2 (en) 2011-10-31 2014-05-13 Scinopharm Taiwan, Ltd. Process for cabazitaxel, and intermediates thereof
CN103874692A (zh) 2011-11-01 2014-06-18 费森尤斯卡比肿瘤学有限公司 卡巴他赛的无定形形式和用于其制备的方法
EP2785701B1 (en) 2011-11-28 2019-01-02 Fresenius Kabi Oncology Limited Crystalline form of carbazitaxel and process for preparation thereof
JP6025861B2 (ja) 2011-12-13 2016-11-16 アベンティス・ファーマ・ソシエテ・アノニム カバジタキセルの結晶形およびこれを調製するための方法
WO2013111157A1 (en) * 2012-01-03 2013-08-01 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
MX2014009610A (es) * 2012-02-10 2015-09-25 Aventis Pharma Sa Nuevos usos pediatricos del cabazitaxel.
US9394266B2 (en) 2012-03-08 2016-07-19 IVAX International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
CN102675257B (zh) * 2012-05-10 2014-07-02 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN102746258B (zh) * 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
US9012665B2 (en) 2012-07-31 2015-04-21 Yung Shin Pharm. Ind. Co., Ltd. Amorphous cabazitaxel
TWI599373B (zh) 2012-08-15 2017-09-21 永信藥品工業股份有限公司 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之穩定醫藥調配物
CN103664836B (zh) * 2012-09-20 2016-04-20 齐鲁制药有限公司 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN103804323A (zh) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 一种卡巴他赛溶剂化物及其制备方法和应用
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法
EP2743264A1 (en) 2012-12-13 2014-06-18 INDENA S.p.A. New crystalline form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
CN103910696B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛异丙醚合物及其结晶
CN103910698B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛丙酮合物及其结晶
EP2777691A1 (en) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2015000165A1 (zh) * 2013-07-04 2015-01-08 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
CN104277014A (zh) * 2013-07-04 2015-01-14 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
EP2865675A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
EP2865674A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. Crystalline solvate forms of Cabazitaxel
CN103601704B (zh) * 2013-11-22 2015-05-06 石家庄智恒医药科技有限公司 无定形卡巴他赛的制备
EP3247350B1 (en) 2015-01-12 2021-12-22 Emcure Pharmaceuticals Limited Liquid formulation of cabazitaxel
JP6841772B2 (ja) * 2015-02-17 2021-03-10 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 前立腺癌の処置におけるカバジタキセルの使用
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
CA3043499A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
AU2017366879C1 (en) 2016-11-29 2022-08-11 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
CN111491635A (zh) 2017-09-01 2020-08-04 显莎制药公司 包含墨蝶呤的药物组合物及其用途
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
WO2020249507A1 (en) 2019-06-11 2020-12-17 Indena S.P.A. Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it
EP3797834A1 (en) 2019-09-25 2021-03-31 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
MA23823A1 (fr) * 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2745814B1 (fr) * 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
EP0982027A1 (en) * 1998-08-17 2000-03-01 Aventis Pharma S.A. Taxoid derivatives for treating abnormal cell proliferation of the brain
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
US6136989A (en) * 1998-12-30 2000-10-24 Phytogen Life Sciences, Incorporated Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material
US5969165A (en) * 1999-01-07 1999-10-19 508037 (Nb) Inc. Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column
ATE256117T1 (de) * 1999-05-17 2003-12-15 Bristol Myers Squibb Co Neue umsetzungsbedingungen für die spaltung von silylethern bei der herstellung von paclitaxel (taxol(r)) und paclitaxel -analogen
RU2284328C2 (ru) * 2001-11-29 2006-09-27 Дайити Фармасьютикал Ко., Лтд. Кристаллы производных таксана и способ их получения

Also Published As

Publication number Publication date
SI1667986T1 (sl) 2013-05-31
WO2005028462A1 (fr) 2005-03-31
AR045667A1 (es) 2005-11-02
LU92172I2 (fr) 2013-05-21
HUS1300025I1 (hu) 2016-08-29
UA87115C2 (ru) 2009-06-25
RS54614B1 (en) 2016-08-31
MY136668A (en) 2008-11-28
BRPI0414492A8 (pt) 2019-01-15
RS20060189A (en) 2008-06-05
US7241907B2 (en) 2007-07-10
EP1667986A1 (fr) 2006-06-14
JP5010279B2 (ja) 2012-08-29
KR20060072147A (ko) 2006-06-27
MXPA06002639A (es) 2006-06-05
FR13C0037I1 (fr) 2013-09-08
TW200524891A (en) 2005-08-01
CA2539309A1 (fr) 2005-03-31
NZ545835A (en) 2009-10-30
PE20050870A1 (es) 2005-11-21
MA28045A1 (fr) 2006-07-03
RU2342373C2 (ru) 2008-12-27
TNSN06086A1 (en) 2007-10-03
HK1093340A1 (en) 2007-03-02
RU2006113122A (ru) 2006-08-27
CN100429207C (zh) 2008-10-29
JP2007505866A (ja) 2007-03-15
CY2013016I2 (el) 2018-01-10
PL1667986T3 (pl) 2013-06-28
AU2004274212B2 (en) 2010-03-04
BE2013C036I2 (no) 2023-12-14
PA8612401A1 (es) 2005-08-04
MEP11708A (en) 2010-06-10
NO2015013I2 (no) 2015-04-22
BRPI0414492A (pt) 2006-11-14
TWI382022B (zh) 2013-01-11
CY2013016I1 (el) 2018-01-10
DK1667986T3 (da) 2013-05-06
NO20061714L (no) 2006-04-19
KR101123588B1 (ko) 2012-03-22
AU2004274212A1 (en) 2005-03-31
LU92172I9 (no) 2019-01-03
PT1667986E (pt) 2013-04-24
CY1114575T1 (el) 2016-10-05
CR8292A (es) 2008-10-15
US20050065138A1 (en) 2005-03-24
ES2403149T3 (es) 2013-05-14
IL174240A0 (en) 2006-08-01
ME00054B (me) 2011-02-10
FR2859996A1 (fr) 2005-03-25
ZA200602255B (en) 2007-07-25
IL174240A (en) 2010-12-30
EP1667986B1 (fr) 2013-01-16
ES2403149T4 (es) 2013-06-24
FR13C0037I2 (fr) 2015-11-20
FR2859996B1 (fr) 2006-02-03
CN1849311A (zh) 2006-10-18
NO335997B1 (no) 2015-04-20
HRP20130322T1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
NO2015013I1 (no) Cabazitaxel acetonat, også betegnet acetonsolvat av cabazitaxel eller acetonsolvat av imetoksydocetaxel, eller acetonsolvat av 4-acetoksy-2¿-benzoyloksy-5ß,20-epoksy-1-hydroksy-ß,10ßdimetoksy-9-oksotaks-11-en-13¿-yl (2R,3S)-3-tertbutoksykarbonylamino-2-hydroksy-3-fenylpropionat
LTPA2019511I1 (lt) Rapamicino darinys, skirtas plaučių vėžio gydymui
EA200702551A1 (ru) Способ получения эпоксида из хлоргидрина
CY1119601T1 (el) Προαγωγεις αποπτωσης
FI20041032A (fi) Elastomeerimodifioidut epoksisiloksaanikoostumukset
CY2015003I2 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
ATE462466T1 (de) Ballonkatheter und herstellungsverfahren dafür
CY1114544T1 (el) Παραγωγα πληρως ν-αποθειωμενων γλυκοζαμινογλυκανων ως αναστολεις ηπαρανασης, τα οποια διαθετουν αντιαγγειογονικη δραστικοτητα και δεν επιφερουν αντιθρομβωτικο αποτελεσμα
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
DK1419154T3 (da) Rapamycin-29-enoler
AU2002246411A1 (en) Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same
CL2004001278A1 (es) COMPOSICION O COMBINACION FARMACEUTICA QUE COMPRENDE (a) DERIVADO DE BENZAMIDA INHIBIDOR DE HISTONA DEACETILASA, (b) CISPLATINO, ETOPOCIDO, CAMPTOTECINA, 5-FLUORURACILO, GEMCITABINA, PACLITAXEL, DOCETAXEL, CARBOPLATINO, OXAPLATINO, DOXORUBICINA O VIN
ATE359787T1 (de) Kontrollierte synthese von ziprasidon
NO20075815L (no) Formuleringer og metoder for behandling av amyloidose
DE50311735D1 (de) Das tissue engineering von knochen
NO20053348D0 (no) Farmasoytisk sammensetning for behandling av virusangrep.
DE60327651D1 (de) Thio-analoga von paclitaxel und deren vorprodukte
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
ATE530547T1 (de) Derivate und analoge von chroman als funktionell selektive alpha2c-adrenorezeptor-agonisten
ITMI20022022A1 (it) Analoghi di nocicettina.
EA200600404A1 (ru) Пероральные препаративные формы кладрибина
DE602004026773D1 (de) Verfahrensherstellung von ethern
ITPS20030026A1 (it) Struttura di osteotomo.
NO20015903L (no) Aminoalkylsubstituerte (benzodioksan-, benzofuran eller benzopyran) derivater
DK1644403T3 (da) Cytotoksiske depsipeptider

Legal Events

Date Code Title Description
MK1K Patent expired